Deregulated hepatic microRNAs underlie the association between non-alcoholic fatty liver disease and coronary artery disease

Liver International

Volumn 36, Issue 8, 2016, Pages 1221-1229

  Braza Boïls, Aitana ^a   Marí Alexandre, Josep ^a   Molina, Pilar ^b   Arnau, Miguel A ^c   Barceló Molina, Moisés ^a   Domingo, Diana ^c   Girbes, Javier ^d   Giner, Juan ^b   Martínez Dolz, Luis ^c   Zorio, Esther ^c  

^a INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL CLÍNICO SAN CARLOS IDISSC   (Spain)

^b Instituto de Medicina Legal   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d HOSPITAL UNIVERSITARIO DR PESET   (Spain)

Author keywords

ischaemic heart disease; microRNAs; steatohepatitis; sudden cardiac death

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICRORNA; MICRORNA 106B 5P; MICRORNA 122 5P; MICRORNA 21 5P; MICRORNA 29C 3P; MICRORNA 33A 5P; MICRORNA 34A 5P; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ABDOMINAL CIRCUMFERENCE; ADULT; ARTICLE; AUTOPSY; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATIONAL STUDY; DISEASE SEVERITY; DYSLIPIDEMIA; FEMALE; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; LIPID ANALYSIS; LIPID METABOLISM; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; OBESITY; SUDDEN CARDIAC DEATH; UPREGULATION;

EID: 84978827347     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13097     Document Type: Article

References (45)

1. Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Task force on sudden cardiac death of the European society of cardiology. Eur Heart J 2001; 22: 1374–450.
2. Morentin B, Audicana C . Population-based study of out-of-hospital sudden cardiovascular death: incidence and causes of death in middle-aged adults. Rev Esp Cardiol 2011; 64: 28–34.
3. Adams LA, Lindor KD . Nonalcoholic fatty liver disease. Ann Epidemiol 2007; 17: 863–9.
4. deAlwis NM, Day CP . Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 2008; 48(Suppl. 1): S104–12.
5. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387–95.
6. Neuschwander-Tetri BA, Caldwell SH . Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202–19.
7. Machado M, Marques-Vidal P, Cortez-Pinto H . Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006; 45: 600–6.
8. Targher G, Bertolini L, Padovani R, et al. Relations between carotid artery wall thickness and liver histology in subjects with non-alcoholic fatty liver disease. Diabetes Care 2006; 29: 1325–30.
9. Targher G, Arcaro G . Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007; 191: 235–40.
10. Duseja A, Singh SP, Saraswat VA, et al. Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology. J Clin Exp Hepatol 2015; 5: 51–68.
11. Santos RD, Agewall S . Non-alcoholic fatty liver disease and cardiovascular disease. Atherosclerosis 2012; 224: 324–5.
12. Goedeke L, Fernández-Hernando C . Regulation of cholesterol homeostasis. Cell Mol Life Sci 2012; 69: 915–30.
13. Zorio E, Medina P, Rueda J, et al. Insights into the role of microRNAs in cardiac diseases: from biological signalling to therapeutic targets. Cardiovasc Hematol Agents Med Chem 2009; 7: 82–90.
14. Bartel DP . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281–97.
15. Bartel DP . MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215–33.
16. Ceccarelli S, Panera N, Gnani D, Nobili V . Dual Role of MicroRNAs in NAFLD. Int J Mol Sci 2013; 14: 8437–55.
17. Cheung O, Puri P, Eicken C, et al. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 2008; 48: 1810–20.
18. Cheung O, Sanyal AJ . Recent advances in nonalcoholic fatty liver disease. Curr Opin Gastroenterol 2010; 26: 202–8.
19. D'Alessandra Y, Carena MC, Spazzafumo L, et al. Diagnostic potential of plasmatic microRNA signatures in stable and unstable angina. PLoS ONE 2013; 8: e80345.
20. D'Alessandra Y, Devanna P, Limana F, et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J 2010; 31: 2765–73.
21. Sotoudehmanesh R, Sotoudeh M, Ali-Asgari A, et al. Silent liver diseases in autopsies from forensic medicine of Tehran. Arch Iran Med 2006; 9: 324–8.
22. Zois CD, Baltayiannis GH, Bekiari A, et al. Steatosis and steatohepatitis in postmortem material from Northwestern Greece. World J Gastroenterol 2010; 16: 3944–9.
23. Goldstein S . The necessity of a uniform definition of sudden coronary death: witnessed death within 1 hour of the onset of acute symptoms. Am Heart J 1982; 103: 156–9.
24. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR . Nonalcoholic steatohepatitis: proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467–74.
25. Stepanova M, Younossi ZM . Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 2012; 10: 646–50.
26. Lin YC, Lo HM, Chen JD . Sonographic fatty liver, overweight and ischaemic heart disease. World J Gastroenterol 2005; 11: 4838–42.
27. Kessler A, Levy Y, Roth A, et al. Increased prevalence of NAFLD in patients with acute myocardial infarction independent of BMI. Hepatology 2005; 42: 623A.
28. Li X, Xia M, Ma H, et al. Liver fat content is associated with increased carotid atherosclerosis in a Chinese middle-aged and elderly population: the Shanghai Changfeng study. Atherosclerosis 2012; 224: 480–5.
29. Dam-Larsen S, Becker U, Franzmann MB, et al. Final results of a long-term, clinical follow-up in fatty liver patients. Scand J Gastroenterol 2009; 44: 1236–43.
30. Schwimmer JB, Deutsch R, Behling C, Lavine JE . Fatty liver as a determinant of atherosclerosis. Hepatology 2005; 42: 610A.
31. Hur W, Lee JH, Kim SW, et al. Downregulation of microRNA-451 in non-alcoholic steatohepatitis inhibits fatty acid-induced proinflammatory cytokine production through the AMPK/AKT pathway. Int J Biochem Cell Biol 2015; 64: 265–76.
32. Yamada H, Ohashi K, Suzuki K, et al. Longitudinal study of circulating miR-122 in a rat model of non-alcoholic fatty liver disease. Clin Chim Acta 2015; 446: 267–71.
33. Xu Y, Zalzala M, Xu J, et al. A metabolic stress-inducible miR-34a-HNF4α pathway regulates lipid and lipoprotein metabolism. Nat Commun 2015; 6: 7466.
34. Sun C, Huang F, Liu X, et al. miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR. Int J Mol Med 2015; 35: 847–53.
35. Pogribny IP, Starlard-Davenport A, Tryndyak VP, et al. Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice. Lab Invest 2010; 90: 1437–46.
36. Min HK, Kapoor A, Fuchs M, et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab 2012; 15: 665–74.
37. Boon RA, Lekushi K, Lechner S, et al. MicroRNA-34a regulates cardiac ageing and function. Nature 2013; 495: 107–10.
38. Alisi A, Da Sacco L, Bruscalupi G, et al. Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease. Lab Invest 2011; 91: 283–93.
39. Csak T, Bala S, Lippai D, et al. microRNA-122 regulates hypoxia-inducible factor-1 and vimentin in hepatocytes and correlates with fibrosis in diet-induced steatohepatitis. Liver Int 2015; 35: 532–41.
40. Elmen J, Lindow M, Schutz S, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008; 452: 896–9.
41. Esau C, Davis S, Murray SF, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006; 3: 87–98.
42. Fernández-Hernando C, Moore KJ . MicroRNA Modulation of cholesterol homeostasis. Arterioscler Thromb Vasc Biol 2011; 31: 2378–82.
43. Lee RC, Feinbaum RL, Ambros V . The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75: 843–54.
44. Bae HJ, Noh JH, Kim JK, et al. MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT1 in hepatocellular carcinoma. Oncogene 2014; 33: 2557–67.
45. Wang CM, Wang Y, Fan CG, et al. miR-29c targets TNFAIP3, inhibits cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma. Biochem Biophys Res Commun 2011; 411: 586–92.